Int J Oncol 63: [Related article:] 123, 2023; DOI:
10.3892/ijo.2023.5571
Subsequently to the publication of the above review,
the authors have contacted the Editorial Office to explain that the
article was regrettably published containing a few errors. First,
on p. 3, left-hand column, the '3. Functions of circRNAs in
OS' section, line 23, the sentence here should have read as
follows (changes shown in bold, where appropriate):
'Circ_0001649 has been reported as a sponge of
various miRNAs that inhibit cell proliferation (62,83).' (i.e.,
mentioning 'Circ_0001649' twice was an error/oversight). Secondly,
in the '4. Mechanisms of circRNAs in OS' section, paragraph
5, line 23 on p. 8, the four consecutive sentences that start on
this line should have read as follows: 'Hsa_circ_0000190 is
significantly downregulated in OS tissues and cell lines. This
circRNA inhibits the Wnt/β-catenin signaling pathway by sponging
miR-767-5p, the target of which is TET1 (61). And
hsa_circ_0002052 can sponge miR-1205, the target of which is
adenomatosis polyposis coli 2 (APC2), a negative regulator of the
Wnt/β-catenin signaling pathway. Hence, hsa_circ_0000190 and
hsa_circ_0002052 can function as inhibitors of the
Wnt/β-catenin signaling pathway by promoting TET1 and APC2
expression via miRNA sponging, ultimately resulting in the delayed
development of OS (50,61).' (i.e., the first sentence was
corrected to read 'Hsa_circ_0000190' and 'hsa_circ_0000190' was
added to the fourth sentence, and ref. 61 was added to the second
sentence in this section, and included with ref. 50 at the end of
the fourth sentence). Thirdly (and finally), changes were required
to both Fig. 3 and its
accompanying legend, and these are featured on the next page;
essentially, 'CircRNA CDR1as (47)' should not have been included in
the Fig. 3 legend as this circRNA
is not described in the figure, and some changes have been made to
the figure itself in terms of wrongly placed lines and arrows.
 | Figure 3Mechanisms of circRNAs in OS.
Hsa_circ_0007534 (46), Circ_ORC2 (51), Circ_001422 (63),
Circ_0001785 (52), Hsa_circ_0005909 (64), Circ_03955 (54),
Circ_001569 (48), Hsa_circ_0002052 (56), Hsa_circ_0009910 (49),
Circ_ANKIB1 (57), Circ_ITCH (53), Hsa_circ_0005909 (55),
Hsa_circ_0002052 (50), Has_circ_0000190 (61), Hsa_circ_0001649 (62)
participate in the occurrence and development of OS by regulating
the JAK-STAT3, NF-κB, PI3K-AKT and Wnt/β-catenin signaling
pathways. SOCS3, suppressor of cytokine signaling 3; STAT3, signal
transducer and activator of transcription 3; HMGA1, high mobility
group AT-hook 1; HMGB1, high mobility group box 1; ZEB1/2, zinc
finger E-box binding homeobox 1/2; PTEN, phosphatase and tensin
homolog; GSK3β, glycogen synthase kinase 3β; HOXB2, homeobox B2;
DKK, Dickkopf; TET1, Tet methylcytosine dioxygenase 1; SFRP2,
secreted frizzled-related protein 2; STX6, syntaxin 6. |
The authors are grateful to the Editor of
International Journal of Oncology for allowing them this
opportunity to publish this Corrigendum, and all the authors agree
with its publication. Furthermore, the authors apologize to the
readership for any inconvenience caused.
